Join Our Newsletter
Get the best of VaccineNation in your inbox
Stay informed. Get the newsletter that gives you an edge in this rapidly changing sector, for free.
MOST POPULAR THIS MONTH
Exclusive interview with Dr Miguel Sanjuan
With just a few weeks left until the World Vaccine Congress in Europe 2022 we are looking forward to hearing from a range of incredible speakers. One such speaker is Dr Miguel Sanjuan, SVP Research and Development at Provention Bio. He will be showcasing a vaccine...
Sabin announces further BARDA funding for trials
In September 2022 the Sabin Vaccine Institute announced that it was “receiving an additional $21.8 million” from the Biomedical Advanced Research and Development Authority (BARDA) in the US. These funds, part of an existing contract, “advance development of a vaccine...
Long Covid: more questions than answers, studies suggest
An article by Gavi in September 2022 explored the few studies that investigate the links between COVID-19 vaccination and Long Covid. WHO’s Dr Janet Diaz described the many possible symptoms of “post COVID-19 condition” or Long Covid, identifying more than 200...
Global Fund Partners announce record funding against disease
In September 2022 the US hosted a “pledging conference” for the Global Fund to Fight AIDS, Tuberculosis, and Malaria. This raised a total of more than $14.25 billion for work over the coming 3 years. The conference united 45 countries as well as private sector...
Uganda declares Ebola outbreak of ‘Sudan’ strain
In September 2022 the WHO announced that health authorities in Uganda had declared an outbreak of Ebola. This follows a case of the Sudan ebolavirus in the Mubende district. Ebola is described by the WHO as a “severe, often fatal illness” in humans and other primates....
CEPI launches funding for Rift Valley fever trials
In September 2022 CEPI announced the launch of its second phase of funding to “advance innovative Rift Valley fever vaccine programmes into clinical trials”. The funding, which includes $35 million in financial support from the EU Horizon Europe programme, reaches a...
White paper from SGS: vaccine development post-pandemic
In a white paper from SGS in September 2022 the importance of “analytical biosafety testing” and “advances in developing scientific technologies” was emphasised as crucial in preparing for the “next pandemic”. The paper reflects that before the COVID-19 pandemic, the...
European biotechs receive EUREKA therapeutic funding
In September 2022 LABIOTECH.EU announced that a partnership between European biotech companies had been awarded a €1.06 million grant from EUREKA Eurostars. CimCure BV, a Dutch Biotech, Covalab, a French biotech, Amsterdam UMC, and the University of Zurich have...
